A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1 Completed 12 enrolled AbbVie

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.

Timeline

Start: 2010-05
Primary completion: 2011-05
Completion: 2011-05

Publications

Results Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014 Dec;39(6):680-4. doi: 10.1111/jcpt.12193. Epub 2014 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Navitoclax	Small molecule	250 mg	Oral
Subject	Rifampin	Small molecule	600 mg	—

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Summary

Timeline

Publications

Drugs

Indications